Your browser doesn't support javascript.
loading
Trends and variation in the use of radiotherapy in non-metastatic prostate cancer: A 12-year nationwide overview from the Netherlands.
Evers, Jelle; Kerkmeijer, Linda G W; van den Bergh, Roderick C N; van der Sangen, Maurice J C; Hulshof, Maarten C C M; Bloemers, Monique C W M; Siesling, Sabine; Aarts, Mieke J; Aben, Katja K H; Struikmans, Henk.
Affiliation
  • Evers J; Netherlands Comprehensive Cancer Organisation (IKNL), Department of Research and Development, Godebaldkwartier 419, 3511 DT Utrecht, the Netherlands; University of Twente, Department of Health Technology and Services Research, Technical Medical Center, Hallenweg 5, 7522 NH Enschede, the Netherlands.
  • Kerkmeijer LGW; Radboud University Medical Center, Department of Radiation Oncology, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands.
  • van den Bergh RCN; St. Antonius Hospital, Department of Urology, Koekoekslaan 1, 3435 CM Nieuwegein, the Netherlands.
  • van der Sangen MJC; Catharina Hospital, Department of Radiation Oncology, Michelangelolaan 2, 5623 EJ Eindhoven, the Netherlands.
  • Hulshof MCCM; Amsterdam University Medical Center, Department of Radiation Oncology, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
  • Bloemers MCWM; The Netherlands Cancer Institute, Department of Radiation Oncology, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.
  • Siesling S; Netherlands Comprehensive Cancer Organisation (IKNL), Department of Research and Development, Godebaldkwartier 419, 3511 DT Utrecht, the Netherlands; University of Twente, Department of Health Technology and Services Research, Technical Medical Center, Hallenweg 5, 7522 NH Enschede, the Netherlands.
  • Aarts MJ; Netherlands Comprehensive Cancer Organisation (IKNL), Department of Research and Development, Godebaldkwartier 419, 3511 DT Utrecht, the Netherlands.
  • Aben KKH; Netherlands Comprehensive Cancer Organisation (IKNL), Department of Research and Development, Godebaldkwartier 419, 3511 DT Utrecht, the Netherlands; Radboud University Medical Center, Radboud Institute for Health Sciences, Geert Grooteplein Zuid 21, 6525 EZ Nijmegen, the Netherlands.
  • Struikmans H; Leiden University Medical Center, Department of Radiation Oncology, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.
Radiother Oncol ; 177: 134-142, 2022 12.
Article in En | MEDLINE | ID: mdl-36328090
ABSTRACT

PURPOSE:

This population-based study describes nationwide trends and variation in the use of primary radiotherapy for non-metastatic prostate cancer in The Netherlands in 2008-2019.

METHODS:

Prostate cancer patients were selected from the Netherlands Cancer Registry (N = 103,059). Treatment trends were studied over time by prognostic risk groups. Multilevel analyses were applied to identify variables associated with external beam radiotherapy (EBRT) and brachy-monotherapy versus no active treatment in low-risk disease, and EBRT versus radical prostatectomy in intermediate and high-risk disease.

RESULTS:

EBRT use remained stable (5-6%) in low-risk prostate cancer and increased from 21% to 32% in intermediate-risk, 37% to 45% in high-risk localized and 50% to 57% in high-risk locally advanced disease. Brachy-monotherapy decreased from 19% to 6% and from 15% to 10% in low and intermediate-risk disease, respectively, coinciding an increase of no active treatment from 55% to 73% in low-risk disease. Use of EBRT or brachy-monotherapy versus no active treatment in low-risk disease differed by region, T-stage and patient characteristics. Hospital characteristics were not associated with treatment in low-risk disease, except for availability of brachy-monotherapy in 2008-2013. Age, number of comorbidities, travel time for EBRT, prognostic risk group, and hospital characteristics were associated with EBRT versus prostatectomy in intermediate and high-risk disease.

CONCLUSION:

Intermediate/high-risk PCa was increasingly managed with EBRT, while brachy-monotherapy in low/intermediate-risk PCa decreased. In low-risk PCa, the no active treatment-approach increased. Variation in treatment suggests treatment decision related to patient/disease characteristics. In intermediate/high-risk disease, variation seems furthermore related to the treatment modalities available in the diagnosing hospitals.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Brachytherapy Type of study: Prognostic_studies Limits: Humans / Male Country/Region as subject: Europa Language: En Journal: Radiother Oncol Year: 2022 Document type: Article Affiliation country: Países Bajos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Brachytherapy Type of study: Prognostic_studies Limits: Humans / Male Country/Region as subject: Europa Language: En Journal: Radiother Oncol Year: 2022 Document type: Article Affiliation country: Países Bajos